220 related articles for article (PubMed ID: 10707561)
1. [Clinical effect and side effect of troglitazone].
Toyota T; Ueno Y
Nihon Rinsho; 2000 Feb; 58(2):376-82. PubMed ID: 10707561
[TBL] [Abstract][Full Text] [Related]
2. Severe but reversible hepatitis induced by troglitazone.
Schiano T; Dolehide K; Hart J; Baker AL
Dig Dis Sci; 2000 May; 45(5):1039-42. PubMed ID: 10795774
[No Abstract] [Full Text] [Related]
3. Hepatic injury due to troglitazone.
Malik AH; Prasad P; Saboorian MH; Thiele DL; Malet PF
Dig Dis Sci; 2000 Jan; 45(1):210-4. PubMed ID: 10695637
[No Abstract] [Full Text] [Related]
4. The rise and fall of troglitazone.
Bailey CJ
Diabet Med; 2000 Jun; 17(6):414-5. PubMed ID: 10975209
[No Abstract] [Full Text] [Related]
5. Troglitazone. Is it all over?
Wagenaar LJ; Kuck EM; Hoekstra JB
Neth J Med; 1999 Jul; 55(1):4-12. PubMed ID: 10431549
[TBL] [Abstract][Full Text] [Related]
6. A novel antidiabetic drug, troglitazone--reason for hope and concern.
Imura H
N Engl J Med; 1998 Mar; 338(13):908-9. PubMed ID: 9516229
[No Abstract] [Full Text] [Related]
7. FDA reviews troglitazone.
Donnelly R
Diabetes Obes Metab; 1999 Mar; 1(2):65-6. PubMed ID: 11220513
[No Abstract] [Full Text] [Related]
8. Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus.
Menon KVN ; Angulo P; Lindor KD
Am J Gastroenterol; 2001 May; 96(5):1631-4. PubMed ID: 11374713
[TBL] [Abstract][Full Text] [Related]
9. Troglitazone: a review of its use in the management of type 2 diabetes mellitus.
Plosker GL; Faulds D
Drugs; 1999 Mar; 57(3):409-38. PubMed ID: 10193691
[TBL] [Abstract][Full Text] [Related]
10. Thiazolidinedione hepatotoxicity: a class effect?
Tolman KG
Int J Clin Pract Suppl; 2000 Oct; (113):29-34. PubMed ID: 11965828
[TBL] [Abstract][Full Text] [Related]
11. [The development of thiazolidinedione drugs as anti-diabetic agents].
Kuzuya T
Nihon Rinsho; 2000 Feb; 58(2):364-9. PubMed ID: 10707559
[TBL] [Abstract][Full Text] [Related]
12. Troglitazone for non-insulin-dependent diabetes mellitus.
Med Lett Drugs Ther; 1997 May; 39(1001):49-51. PubMed ID: 9164446
[No Abstract] [Full Text] [Related]
13. Thiazolidinediones for type 2 diabetes. New agents reduce insulin resistance but need long term clinical trials.
Krentz AJ; Bailey CJ; Melander A
BMJ; 2000 Jul; 321(7256):252-3. PubMed ID: 10915108
[No Abstract] [Full Text] [Related]
14. Hepatotoxicity with thiazolidinediones: is it a class effect?
Scheen AJ
Drug Saf; 2001; 24(12):873-88. PubMed ID: 11735645
[TBL] [Abstract][Full Text] [Related]
15. Late-onset troglitazone-induced hepatic dysfunction.
Bell DS; Ovalle F
Diabetes Care; 2000 Jan; 23(1):128-9. PubMed ID: 10857986
[No Abstract] [Full Text] [Related]
16. Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration.
Kohlroser J; Mathai J; Reichheld J; Banner BF; Bonkovsky HL
Am J Gastroenterol; 2000 Jan; 95(1):272-6. PubMed ID: 10638596
[TBL] [Abstract][Full Text] [Related]
17. Subacute hepatic failure associated with a new antidiabetic agent, troglitazone: a case report with autopsy examination.
Fukano M; Amano S; Sato J; Yamamoto K; Adachi H; Okabe H; Fujiyama Y; Bamba T
Hum Pathol; 2000 Feb; 31(2):250-3. PubMed ID: 10685643
[TBL] [Abstract][Full Text] [Related]
18. Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients.
Kumar S; Prange A; Schulze J; Lettis S; Barnett AH
Diabet Med; 1998 Sep; 15(9):772-9. PubMed ID: 9737807
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of troglitazone, a PPAR-gamma agonist, in patients with hepatic insufficiency.
Ott P; Ranek L; Young MA
Eur J Clin Pharmacol; 1998 Sep; 54(7):567-71. PubMed ID: 9832300
[TBL] [Abstract][Full Text] [Related]
20. Fatal hepatotoxicity associated with troglitazone.
Vella A; de Groen PC; Dinneen SF
Ann Intern Med; 1998 Dec; 129(12):1080. PubMed ID: 9867776
[No Abstract] [Full Text] [Related]
[Next] [New Search]